News

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company focused on harnessing the power of the immune system to address life-threatening diseases, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD). RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for AE-COPD, acute graft-versus-host disease (aGvHD), hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.

“Patients with chronic obstructive pulmonary disease (COPD) face the persistent threat of hospitalization, mechanical ventilation and death from an acute exacerbation, an acute worsening of symptoms triggered by a viral or bacterial infection, or environmental irritant. Once triggered, an acute exacerbation of COPD is driven by neutrophil effectors including myeloperoxidase, neutrophil elastase, NETosis, and complement activation, and this underlying pathogenesis leads to poorer quality of life for patients and an increased risk of death. With current treatment options limited and poorly matched to the disease process, we believe RLS-0071 has the potential to fill this unmet need given its dual-targeting and rapid mechanism of action,” said ReAlta Chief Executive Officer Ulrich Thienel, MD, PhD. “This FDA clearance marks an important new milestone for ReAlta as we explore the potential of RLS-0071 across multiple therapeutic areas.”

The Phase 2 clinical trial will be a randomized, double-blind, placebo-controlled trial in hospitalized patients with AE-COPD. Patients will receive either RLS-0071 or placebo as an add-on to standard of care therapy. The primary endpoint of the study is safety. Key secondary endpoints include biomarkers of inflammation, physiological response to RLS-0071 compared to placebo, as well as clinical progression and resolution.

Learn more here.

Recent News

11/30/2023

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding

11/30/2023

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research

11/27/2023

cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged